The overexpression of Rab9 promotes tumor progression regulated by XBP1 in breast cancer
Authors Liu Y, Wang X, Zhang Z, Xiao B, An B, Zhang J
Received 13 August 2018
Accepted for publication 13 January 2019
Published 4 March 2019 Volume 2019:12 Pages 1815—1824
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Yao Dai
Yansong Liu,1 Xin Wang,2 Zhonghua Zhang,3 Bin Xiao,4 Baoming An,5 Jun Zhang6
1Breast Department, Shandong Cancer Hospital, Affiliated to Shandong University, Shandong, China; 2Breast Department, Yinan Country People’s Hospital, Shandong, China; 3Breast Department, Dongping Country People’s Hospital, Shandong, China; 4Breast Department, Shanxian Hygeia Hospital, Shandong, China; 5Breast Department, Wulian Country People’s Hospital, Shandong, China; 6Breast Department, Zhangqiu Hospital of Chinese Medicine, Shandong, China
Background: Rab9 is a small GTPase that localizes to the trans-Golgi Network (TGN) and late endosomes and is involved in the recycling of mannose-6-phosphate receptors (MPRs).
Materials and methods: To determine new treatment strategies for breast cancer and to elucidate the mechanism underlying the phenomenon, we investigated the effects of Rab9 in the human breast cancer cell lines MCF7 and MDA-MB-231.
Results: We observed that knockdown of Rab9 inhibited the survival and proliferation of MCF7 and MDA-MB-231 cells, whereas Rab9 overexpression facilitated cell survival and proliferation by inducing or suppressing apoptosis. These results were further confirmed by the Bax/Bcl-2 ratio in affected MCF7 and MDA-MB-231 cells, which demonstrated whether the mitochondrial apoptotic pathway was triggered. Furthermore, the AKT/PI3K pathway is implicated in cell growth and survival and Rab9 changed the expression and phosphorylation of PI3K signaling pathway members. XBP1 is a key regulator of Rab9 and further confirmed that Rab9 play important roles in breast cancer tumorigenesis.
Conclusion: These data suggest that Rab9 is a good candidate for a novel therapeutic strategy for the treatment of breast cancer.
Keywords: transcription factor, proliferation, MCF7, MDA-MB-231
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]